Internship

Intern – Corporate Development

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Full-time onsite work at Cytokinetics’ South San Francisco headquarters for approximately 12 weeks.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • College or graduate student, with responsibilities tailored accordingly
  • Work full-time on site from Cytokinetics’ South San Francisco headquarters
  • Positive attitude, attention to detail and interest in helping others
  • Team player with strong interpersonal and communication skills
  • Biological knowledge necessary to understand the drug pipeline/portfolio of Cytokinetics and potential partners
  • Excellent analytical capabilities required
  • Ability to summarize or simplify complex concepts in words and graphics and to “think on your feet”
Responsibilities
  • Assist the team responsible for identifying and evaluating licensing and collaboration opportunities and negotiating term sheets and agreements
  • Perform background research on potential partners, including public and proprietary database searches
  • Update internal tracking documents to ensure all information accurately reflects the current situation
  • Support initiatives to enhance alliance management capabilities
  • Inform Cytokinetics’ cross-functional strategic planning
  • Generate and deliver impactful presentations to senior management and key decision-makers

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?